Published on November 16, 2009 at 10:02 AM
Gentium S.p.A. (Nasdaq: GENT) announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.
The results of these trials will be highlighted in two separate oral presentations on Monday, December 7, 2009 during the session, “Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Approaches to Predict, Assess and Reduce Transplant Related Organ Toxicities” in the Ernest N. Morial Convention Center, 353-355. Details are as follows:
- “Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantation: Results of a Prospective Phase II/III Randomized, Multicenter Study” to be presented at 5:30 PM CT by Selim Corbacioglu, M.D., Pediatrics, University of Ulm, Germany
Abstract: http://ash.confex.com/ash/2009/webprogram/Paper22303.html
- “Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control” to be presented at 5:45 PM CT by Paul G. Richardson, M.D., Dana-Farber Cancer Institute, Boston, MA
Abstract: http://ash.confex.com/ash/2009/webprogram/Paper22224.html
Defibrotide will also be featured in the press conference entitled, “Transplantation: Preventing Complications and Improving Outcomes” on Saturday, December 5th from 2:00 PM - 3:00 PM CT in the Ernest N. Morial Convention Center, Room 350.
Source Gentium S.p.A.,